Validation of [123I]β-CIT SPECT to serotonin transporters in vivo in humans: A double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram

Neuropsychopharmacology

Volumn 30, Issue 5, 2005, Pages 996-1005

  De Win, Maartje M L ^a,b   Habraken, Jan B A ^a   Reneman, Liesbeth ^a   Van Den Brink, Wim ^a   Den Heeten, Gerard J ^a   Booij, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Graduate School of Neurosciences   (Netherlands)

Author keywords

123I CIT SPECT; Citalopram; DAT; Serotonin; SERT; SSRI

Indexed keywords

2BETA CARBOMETHOXY 3BETA(4 IODOPHENYL)TROPANE; CITALOPRAM; DOPAMINE TRANSPORTER; IODINE 123; PLACEBO; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; CEREBELLUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG PROTEIN BINDING; HUMAN; HYPOTHALAMUS; IN VIVO STUDY; MALE; MESENCEPHALON; NON INVASIVE MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS;

ADOLESCENT; ADULT; BRAIN; BRAIN CHEMISTRY; CITALOPRAM; COCAINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 17644395630     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300683     Document Type: Article

References (49)

1. 3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 486: 261-268.
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571.
3. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002). Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22: 6766-6772.
4. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 12: 27-36.
5. 123I]FP-[CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 133-140.
6. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 94: 137-146.
7. 3H]paroxetine. Neuroscience 27: 473-496.
8. 123I]β-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol 14: 185-189.
9. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse 2: 93-103.
10. Friston KJ, Holmes AP, Poline JB, Price CJ, Frith CD (1996). Detecting activation in PET and fMRI: levels of inference and power. Neuroimage 4: 223-235.
11. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frakowiak RSJ (1995). Statistical parametric maps in functional imaging: general approach. Hum Brain Mapp 2: 189-210.
12. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R et al (1998). Serotonergic function after (±)3,4-methylene-dioxymethamphetamine ('ecstasy') in humans. Int Clin Psychopharmacol 13: 1-9.
13. 125I]β-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol 24: 629-634.
14. Hatzidimitriou G, McCann UD, Ricaurte GA (1999). Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
15. Heinz A, Jones DW (2000). Serotonin transporters in ecstasy users. Br J Psychiatry 176: 193-195.
16. Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB et al (1998). Reduced central serotonin transporters in alcoholism. Am J Psychiatry 155: 1544-1549.
17. Johnson AM (1991). The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals. In: Heighner JP, Boyer WF (eds). Perspectives in Psychiatry, Vol 1. Selective Serotonin Reuptake Inhibitors. Wilet: Chichester. pp 37-70.
18. Kish SJ (2002). Effects of MDMA (ecstasy) use and abstention on serotonin neurons. Lancet 359: 1616.
19. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000). Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 55: 294-296.
20. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM et al (2003). Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28: 413-420.
21. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309.
22. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14: 982-994.
23. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS (1996). Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276: 855-865.
24. Lucki I (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44: 151-162.
25. 123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 44: 1090-1098.
26. 11C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835.
27. Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD et al (2000). 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 3: 249-254.
28. Parrott AC (2000). Human research on MDMA (3,4- methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24.
29. 11C]McN 5652. J Nucl Med 41: 1465-1477.
30. 123I-β- CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 41: 36-44.
31. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G et al (1995). CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 100: 247-256.
32. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB et al (2001b). Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869.
33. 123I]β-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46: 199-205.
34. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ et al (2001a). Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'): preliminary findings. Arch Gen Psychiatry 58: 901-906.
35. Ricaurte GA, McCann UD (2001). Assessing long-term effects of MDMA (Ecstasy). Lancet 358: 1831-1832.
36. Ricaurte GA, Yuan J, McCann UD (2000). 3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5-10.
37. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse 11: 134-139.
38. 125I]RTI-55 Synapse 16: 263-268.
39. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S et al (1994). Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-β-CIT in healthy human subjects. J Nucl Med 35: 764-770.
40. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999). Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69.
41. 125I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 62: 549-556.
42. Suhara T, Sudo Y, Yoshida K, Okubo Y, Fukuda H, Obata T et al (1998). Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 351: 332-335.
43. 11C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43: 678-692.
44. Talairach J, Tournoux P (1988). Co-Planar Stereotaxic Atlas of the Human Brain. Thieme: New York.
45. Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brücke T, Kasper S (1999). In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 9: 177-179.
46. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L et al (2003). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85-96.
47. Verbaten MN (2003). Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharmacol 18: 281-290.
48. Wenk GL (2003). Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 64(Suppl 9): 7-10.
49. Worsley KJ, Evans AC, Marrett S, Neelin P (1992). A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 12: 900-918.